Loading
companiesCompany
Agendia
Dutch maker of MammaPrint, the 70-gene breast cancer test validated in the MINDACT trial.
Overview
Spun out of the Netherlands Cancer Institute, Agendia developed MammaPrint (FDA-cleared 2007, the first cleared multigene prognostic test) and the BluePrint molecular subtyping assay, and sponsored MINDACT with the EORTC. It also runs the FLEX registry collecting whole-transcriptome data on MammaPrint patients.
Headquarters
Amsterdam / Irvine, CA, NL
Scorecard
All companies#457of 1244 companies, score 6
- modalities +2
- regions +1
- registry trials +3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Website
Founded
2003
EstablishedGene-expression prognostic assay
A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.
Similar pages
- TechnologyGene-expression prognostic assays
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonRené Bernards
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- PairingGene-expression assay → chemotherapy omission
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- TreatmentProsigna (PAM50)
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonCarlos Caldas
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- TreatmentEndoPredict
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- CompanyLucence
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonAleix Prat
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
drugs
EstablishedGene-expression prognostic assay